Jubilant Pharma Singapore is set to sell its entire 25.8% stake in Sofie Biosciences, with the anticipated proceeds reaching up to $139.4 million.
Sofie Biosciences is scheduled to merge with Trilantic North America by June 30.
If the merger transaction falls through, Jubilant Pharma Singapore is poised to receive termination-related fees of up to $7 million from Sofie.
Bringing you the latest updates on finance, economies, stocks, bonds, and more. Stay informed with timely insights.
Be First to Comment